SCHEMBL24656305

SCHEMBL24656305

Cn1c(=O)oc2c(C(C)(C)C)cccc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 1/20 0.38
DRD2 P14416 1/20 0.38
CA2 P00918 1/20 0.35
JAK2 O60674 1/20 0.35
BTK Q06187 1/20 0.35
CA12 O43570 1/20 0.34
BRD4 O60885 1/20 0.34
BRPF1 P55201 1/20 0.34
CA9 Q16790 1/20 0.34
KAT2B Q92831 1/20 0.34
BRD9 Q9H8M2 1/20 0.34
ALDH1A1 P00352 4/20 0.34
HPGD P15428 2/20 0.34
PRKDC P78527 1/20 0.33
TP53 P04637 2/20 0.32
MAPT P10636 1/20 0.32
GABRA1 P14867 1/20 0.32
GABRB2 P47870 1/20 0.32
PKM P14618 4/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13681603 0.78 HTR1A (0.41) HTR1ADRD2JAK2BTKCA12
SCHEMBL14867215 0.77 ASAH1 (0.42) HTR1ADRD2JAK2BTKCA12
SCHEMBL14034640 0.75 HTR1A (0.40) HTR1ADRD2JAK2BTKCA12
SCHEMBL5543874 0.75 JAK2 (0.48) HTR1ADRD2JAK2BTKCA12
SCHEMBL7978985 0.75 HTT (0.44) HTR1ADRD2CA2JAK2BTK
SCHEMBL5546415 0.75 JAK2 (0.42) HTR1ADRD2JAK2BTKCA12
SCHEMBL5542528 0.75 HTR1A (0.42) HTR1ADRD2CA2JAK2BTK
SCHEMBL21893887 0.72 HTR1A (0.38) HTR1ADRD2JAK2BTKCA12
SCHEMBL30751789 0.72 CYP2A6 (0.47) CA2CA12CA9ALDH1A1HPGD
SCHEMBL25536906 0.72 CA2 (0.35) CA2ALDH1A1HPGDPRKDCTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11820766-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 US disclosed
US-11820766-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 US disclosed
US-20230203060-A1 FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2023-06-29 US disclosed
US-20230203060-A1 FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2023-06-29 US disclosed
US-20230145249-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-05-11 US disclosed
US-20230145249-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-05-11 US disclosed
US-20220332713-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2022-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220332713-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP HTR1A 192/4885DRD2 955/4885CA2 4029/4885
US-20230145249-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP HTR1A 192/4885DRD2 955/4885CA2 4029/4885
US-20230203060-A1 FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF KRAS, NRAS, TP53 HTR1A 4276/4885DRD2 3244/4885CA2 3037/4885
US-11820766-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP HTR1A 192/4885DRD2 955/4885CA2 4029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.